Cardioangiological Center Bethanien (CCB), Im Prüfling 23, 60389, Frankfurt, Germany.
Division of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, University Hospital Freiburg, Bad Krozingen, Germany.
Clin Res Cardiol. 2021 Nov;110(11):1832-1840. doi: 10.1007/s00392-021-01929-5. Epub 2021 Aug 26.
We assessed possible myocardial involvement in previously cardiac healthy post-COVID patients referred for persisting symptoms with suspected myocarditis.
Prior studies suggested myocardial inflammation in patients with coronavirus-induced disease 2019 (COVID-19). However, the prevalence of cardiac involvement among COVID patients varied between 1.4 and 78%.
A total of 56 post-COVID patients without previous heart diseases were included consecutively into this study. All patients had positive antibody titers against SARS-CoV-2. Patients were referred for persistent symptoms such as chest pain/discomfort, shortness of breath, or intolerance to activity. All patients underwent standardized cardiac assessment including electrocardiogram (ECG), cardiac biomarkers, echocardiography, and cardiac magnetic resonance (CMR).
56 Patients (46 ± 12 years, 54% females) presented 71 ± 66 days after their COVID-19 disease. In most patients, the course of COVID-19 was mild, with hospital treatment being necessary in five (9%). At presentation, patients most often reported persistent fatigue (75%), chest pain (71%), and shortness of breath (66%). Acute myocarditis was confirmed by T1/T2-weighed CMR and elevated NTpro-BNP levels in a single patient (2%). Left ventricular ejection fraction was 56% in this patient. Additional eight patients (14%) showed suspicious CMR findings, including myocardial edema without fibrosis (n = 3), or non-ischemic myocardial injury suggesting previous inflammation (n = 5). However, myocarditis could ultimately not be confirmed according to 2018 Lake Louise criteria; ECG, echo and lab findings were inconspicuous in all eight patients.
Among 56 post-COVID patients with persistent thoracic complaints final diagnosis of myocarditis could be confirmed in a single patient using CMR.
我们评估了先前患有 COVID 的、心脏健康的、因疑似心肌炎而持续存在症状的患者是否存在心肌受累的可能。
先前的研究表明,患有 2019 年冠状病毒病(COVID-19)的患者存在心肌炎症。然而,COVID 患者的心脏受累发生率在 1.4%到 78%之间变化不一。
本研究连续纳入了 56 例无先前心脏病的 COVID 后患者。所有患者均具有针对 SARS-CoV-2 的抗体滴度阳性。患者因持续性胸痛/不适、呼吸急促或活动不耐受等症状而被转介。所有患者均接受了包括心电图(ECG)、心脏标志物、超声心动图和心脏磁共振(CMR)在内的标准化心脏评估。
56 例患者(46±12 岁,54%为女性)在 COVID-19 发病后 71±66 天就诊。在大多数患者中,COVID-19 的病程较轻,5 例(9%)需要住院治疗。就诊时,患者最常报告持续性疲劳(75%)、胸痛(71%)和呼吸急促(66%)。1 例患者(2%)通过 T1/T2 加权 CMR 和升高的 NTpro-BNP 水平确诊为急性心肌炎。该患者的左心室射血分数为 56%。另外 8 例(14%)患者的 CMR 检查结果可疑,包括无纤维化的心肌水肿(n=3)或提示先前炎症的非缺血性心肌损伤(n=5)。然而,根据 2018 年的莱克·路易斯标准,最终未能确诊心肌炎;所有 8 例患者的心电图、超声心动图和实验室检查结果均无明显异常。
在 56 例因持续性胸部不适而就诊的 COVID 后患者中,仅有 1 例患者通过 CMR 确诊为心肌炎。